Persistent URL of this record https://hdl.handle.net/1887/101633
In Collections
This item can be found in the following collections:
![SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, PROVIDES SIGNIFICANT AND SUSTAINED INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF INHIBITORS OR CONCOMITANT METHOTREXATE: A PHASE 3 RANDOMIZED, DOUBLE-BLIN](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
SECUKINUMAB, A MONOCLONAL ANTIBODY TO INTERLEUKIN-17A, PROVIDES SIGNIFICANT AND SUSTAINED INHIBITION OF JOINT STRUCTURAL DAMAGE IN ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF PRIOR TNF INHIBITORS OR CONCOMITANT METHOTREXATE: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
- All authors
- Collins, A.; Heijde, D. van der; Landewe, R.; Mease, P.; McInnes, I.; Conaghan, P.; Pricop, L.; Ligozio, G.; Richards, H.; Mpofu, S.
- Date
- 2015-05-31
- Volume
- 45
- Pages
- 42 - 43